CVS announced today that it was selected by the US Department of Health & Human Services to administer the recent Eli Lilly monoclonal antibody treatment to patients in long-term care facilities and in their homes. Coram, the specialty pharmacy & infusion care business of CVS will administer the intravenous therapy. Coram has over 800 trained nurses in the US. Coram will begin administering 1,000 doses of monoclonal antibody therapies for the treatment of COVID-19 in seven cities and their surrounding communities starting Thursday, December 3, including Boston, Chicago, Cleveland, Los Angeles, Milwaukee, Minneapolis and Tampa.
This is a good example of CVS diversified health business, and how it can meet patients needs in various ways.
Julie S. Praline
Director, Equity Analyst
Direct: 617.226.0025
Fax: 617.523.8118
Crestwood Advisors
One Liberty Square
Suite 500
Boston, MA 02109